Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13846211 | 0.84 | KMT2A (0.60) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL646758 | 0.82 | RAB9A (0.46) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL16298846 | 0.82 | HDAC6 (0.49) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL7471122 | 0.82 | SMN1; SMN2 (0.46) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL19771902 | 0.81 | KMT2A (0.47) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL2611134 | 0.79 | KMT2A (0.54) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL19771915 | 0.79 | SMN1; SMN2 (0.44) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL18367843 | 0.79 | SMN1; SMN2 (0.44) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL10066462 | 0.79 | LTA4H (0.48) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 | |
| SCHEMBL27679605 | 0.79 | RAB9A (0.44) | KMT2ARAB9ANPC1SMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1537105-A | Quinazolines useful as MMP-13 inhibitors | ��������ʲ��������ι�˾ | 2004-10-13 | — | — | CN | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | KMT2A 3258/4885RAB9A 1888/4885NPC1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.